Area of research
Biotechnology · Genetics
Research interest
Research interests include Cancer Research and Treatments, Virus-based gene therapy research, RNA Interference and Gene Delivery, and Drug Transport and Resistance Mechanisms.
MACC1 Regulates LGR5 to Promote Cancer Stem Cell Properties in Colorectal Cancer
Induction of circulating ABCB1 transcripts under platinum-based chemotherapy indicates poor prognosis and a bone micrometastatic phenotype in ovarian cancer patients
Activation of gp130 signaling in T cells drives T <sub>H</sub> 17-mediated multi-organ autoimmunity
MACC1 revisited – an in-depth review of a master of metastasis
Broadening the Scope of Sapofection: Cationic Peptide-Saponin Conjugates Improve Gene Delivery <i>In Vitro</i> and <i>In Vivo</i>
Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis—Inducing Genes S100A4 and MACC1
Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis
GIPC1 regulates MACC1-driven metastasis
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker
Real‐world evidence for preventive effects of statins on cancer incidence: A trans‐Atlantic analysis
Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis
Radiofrequency Electromagnetic Fields Cause Non-Temperature-Induced Physical and Biological Effects in Cancer Cells
Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade
S100A4 Is a Strong Negative Prognostic Marker and Potential Therapeutic Target in Adenocarcinoma of the Stomach and Esophagus
Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas
A Brief Introduction to Current Cancer Gene Therapy
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies
M01 as a novel drug enhancer for specifically targeting the blood-brain barrier.
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis
Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models
Suicide nanoplasmids coding for ribosome-inactivating proteins
Real-world Evidence for Preventive Effects of Statins on Cancer Incidence: A Trans-Atlantic Analysis
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy
Small Ones to Fight a Big Problem—Intervention of Cancer Metastasis by Small Molecules
Decoding and targeting the molecular basis of MACC1-driven metastatic spread: Lessons from big data mining and clinical-experimental approaches
Abstract 4525: Modulating chemoresistance: Uncovering the role of mutant SMAD4<sup>R361H</sup>in colorectal cancer using PDO and PDX models
Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial